Third project for Takeda Pharma accomplished with success

On 12 April 2019, the opening ceremony of the new part of the Takeda Pharma liquid forms production building took place in Łyszkowice.
MCKB, the General Contractor of the investment, was represented by: Piotr Grabowicz - President of the Board, Krzysztof Gromek - Vice-President of the Board and Michał Frandzel - Management Board Member.

The extension of the production building was completed in a record time of only 11 months. The existing 3-storey building was extended by 18 metres and its area increased by 1500 m². Additionally, 1000 m² of the existing production area was rebuilt. The construction works were carried out within the area of the operating plant.

Dawid Mazurek, Plant Director of Takeda Pharma, said that the aim of the investment was to raise manufacturing standards, adapt to the latest legal requirements (e.g. products serialization) and increase safety standards.

Takeda's pharmaceutical products are marketed in around 50 countries worldwide.
The pharmaceutical factory in Łyszkowice produces liquid and solid forms of medicines for the needs of the Takeda group and provides contract manufacturing services for the entities outside the Group.
Amol, Vitabuerlecithin and Multisanostol are among the best-known products on the Polish market.